Metformin usually adequate for control of gestational diabetes

August 18, 2013
Metformin usually adequate for control of gestational diabetes
Among women with gestational diabetes mellitus, those receiving metformin achieve lower mean glucose levels compared with those receiving insulin, but some require supplemental insulin therapy, according to research published in the July issue of the American Journal of Obstetrics & Gynecology.

(HealthDay)—Among women with gestational diabetes mellitus, those receiving metformin achieve lower mean glucose levels compared with those receiving insulin, but some require supplemental insulin therapy, according to research published in the July issue of the American Journal of Obstetrics & Gynecology.

Cristiane Pavão Spaulonci, M.D., of the University of São Paulo in Brazil, and colleagues randomly assigned women with gestational diabetes who failed to achieve glycemic control with diet and exercise to therapy with either metformin (47 patients) or insulin (47 patients).

The researchers found that mean , amount of weight gain, and rate of neonatal hypoglycemia were all significantly lower in women receiving metformin compared with those receiving insulin. About 26 percent of the women receiving metformin needed supplemental to achieve glycemic control. Logistic regression analysis showed that earlier gestational age at diagnosis and higher mean pretreatment glucose level increased the probability of need for supplemental insulin.

"We believe that a long-term follow-up is needed, but a discussion by specialist teams on the use of metformin as a first-line drug in the treatment of patients with would be of great usefulness for patients and doctors," the authors write.

Explore further: Neonatal size unaffected by gestational diabetes drugs

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Neonatal size unaffected by gestational diabetes drugs

March 8, 2013
(HealthDay)—Women with gestational diabetes mellitus treated with metformin or insulin have similar changes in markers of metabolic status and no differences in offspring birth weight, according to a study published in ...

Added benefit of lixisenatide is not proven

August 2, 2013
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together ...

Insulin LY2605541 tops glargine for glycemic control in T1DM

January 13, 2013
(HealthDay)—For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 ...

Early intensive diabetes therapy preserves beta-cell function

July 6, 2012
(HealthDay) -- Early, intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy preserves β-cell function for at least 3.5 years, according to a study published in the July issue ...

Added benefit of saxagliptin/metformin combination is not proven

April 29, 2013
The fixed combination of the drugs saxagliptin and metformin (Komboglyze) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the "Act ...

Imeglimin beneficial as add-on to metformin in T2DM

December 14, 2012
(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to ...

Recommended for you

Screen time linked to diabetes

July 28, 2017
Daily screen time of three or more hours is linked to several risk factors associated with the development of diabetes in children, according to a study by St George's, University of London.

Diabetes can be tracked with our Google searches

July 26, 2017
The emergence of Type 2 Diabetes could be more effectively monitored using our Google searches—helping public health officials keep track of the disease and halt its spread—according to research by the University of Warwick.

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.